1 week Ago By Defense World Staff
JPMorgan Chase & Co. decreased its holdings in Certara, Inc. ( NASDAQ:CERT – Free Report ) by 36.
5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,458,539 shares of the company’s stock after selling 1,413,976 shares during the quarter. JPMorgan Chase & Co.
owned 1.53% of Certara worth $26,183,000 at the end of the most recent reporting period. A number of other hedge funds also recently bought and sold shares of the business.
Venturi Wealth Management LLC raised its stake in shares of Certara by 839.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after buying an additional 2,509 shares during the period.
Blue Trust Inc. increased its holdings in Certara by 20.9% in the 4th quarter.
Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after acquiring an additional 822 shares in the last quarter. ANTIPODES PARTNERS Ltd raised its position in Certara by 204.
7% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock worth $58,000 after acquiring an additional 3,656 shares during the period. KBC Group NV lifted its holdings in Certara by 64.
1% during the fourth quarter. KBC Group NV now owns 7,998 shares of the company’s stock valued at $85,000 after purchasing an additional 3,125 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Certara by 442.
2% in the fourth quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after purchasing an additional 6,868 shares during the period. Hedge funds and other institutional investors own 73.
96% of the company’s stock. Wall Street Analyst Weigh In CERT has been the subject of several research analyst reports. TD Cowen began coverage on shares of Certara in a research report on Thursday, February 27th.
They set a “buy” rating and a $16.00 price target for the company. Stephens reissued an “overweight” rating and set a $17.
00 target price on shares of Certara in a report on Thursday, February 27th. Barclays lifted their price target on Certara from $12.00 to $13.
00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Finally, William Blair reissued a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock.
According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $15.83.
Certara Price Performance NASDAQ:CERT opened at $9.05 on Wednesday. Certara, Inc.
has a one year low of $8.72 and a one year high of $19.18.
The stock has a market cap of $1.46 billion, a PE ratio of -45.25, a P/E/G ratio of 9.
29 and a beta of 1.64. The company has a debt-to-equity ratio of 0.
28, a quick ratio of 2.86 and a current ratio of 2.86.
The stock has a 50 day moving average price of $11.87 and a 200 day moving average price of $11.37.
About Certara ( Free Report ) Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. Featured Articles Five stocks we like better than Certara 5 Top Rated Dividend Stocks to Consider Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential Bank Stocks – Best Bank Stocks to Invest In Qualcomm Breaks Down But RSI Signals It’s Severely Oversold What Are Dividends? Buy the Best Dividend Stocks Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.
com's FREE daily email newsletter ..
